Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Stock Has Consensus Target Price of $52.83 According to Brokerages

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $52.83.

PTHS has been the subject of a number of recent research reports. Zacks Research lowered shares of Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 7th. Lake Street Capital cut their price objective on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Finally, Oppenheimer reduced their target price on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday, August 14th.

Pelthos Therapeutics Stock Performance

NYSEAMERICAN:PTHS opened at $17.00 on Friday. The business has a 50 day moving average of $22.51 and a 200 day moving average of $25.02. The company has a market capitalization of $65.11 million, a price-to-earnings ratio of -0.78 and a beta of 3.07. Pelthos Therapeutics has a 1-year low of $16.94 and a 1-year high of $37.50. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its earnings results on Thursday, August 13th. The company reported ($6.62) earnings per share (EPS) for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. The firm had revenue of $15.60 million during the quarter. On average, sell-side analysts predict that Pelthos Therapeutics will post -15.22 earnings per share for the current fiscal year.

Institutional Trading of Pelthos Therapeutics

An institutional investor recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE grew its stake in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,919 shares of the company’s stock after buying an additional 4,819 shares during the quarter. Pale Fire Capital SE owned 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).